Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury.
FTY720
S1P1
gut hypoxia-reperfusion
inflammation
ozanimod
sphingosine-1-phosphate
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
09 Oct 2020
09 Oct 2020
Historique:
received:
31
07
2020
revised:
24
09
2020
accepted:
07
10
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
15
10
2020
Statut:
epublish
Résumé
Mesenteric ischemia/reperfusion (I/R), following the transient deprivation of blood flow to the gut, triggers an acute flogistic process involving the disruption of endothelial and epithelial barriers integrity, the activation of immune cells, and the abundant release of inflammatory mediators. Among them, the lipid mediator sphingosine-1-phosphate (S1P) is involved in maintaining epithelial and endothelial barrier integrity and in governing the migration of immune cells through the interaction with S1P
Identifiants
pubmed: 33050288
pii: ph13100298
doi: 10.3390/ph13100298
pmc: PMC7601119
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : GR-2011-02346974
Références
FASEB J. 2019 Feb;33(2):1711-1726
pubmed: 30188757
Microcirculation. 2002 Apr;9(2):99-109
pubmed: 11932777
Acta Physiol (Oxf). 2018 Jan;222(1):
pubmed: 28231640
Neuropharmacology. 2017 Feb;113(Pt B):597-607
pubmed: 27825807
Pharmacol Ther. 2007 Jul;115(1):84-105
pubmed: 17561264
Transplant Proc. 2001 Feb-Mar;33(1-2):857-9
pubmed: 11267102
Curr Atheroscler Rep. 2016 Jun;18(6):31
pubmed: 27115142
Drug Discov Today. 2018 Jul;23(7):1416-1425
pubmed: 29857163
Am J Transplant. 2005 Jan;5(1):40-9
pubmed: 15636610
Mediators Inflamm. 2017;2017:6059203
pubmed: 28848247
Shock. 2005 Mar;23(3):258-63
pubmed: 15718925
Shock. 2014 Nov;42(5):448-55
pubmed: 25004059
Pharmacol Ther. 2018 May;185:34-49
pubmed: 29127024
Gastroenterology. 1984 Dec;87(6):1344-50
pubmed: 6092199
Inflammation. 2012 Feb;35(1):158-66
pubmed: 21302134
Pharmacol Ther. 2020 Mar;207:107464
pubmed: 31863815
Pharmacol Res. 2014 Mar;81:17-25
pubmed: 24548822
Kidney Int. 2011 Dec;80(12):1315-27
pubmed: 21849969
Prostaglandins Other Lipid Mediat. 2020 Aug;149:106436
pubmed: 32173486
Am J Physiol Lung Cell Mol Physiol. 2015 Jun 15;308(12):L1245-52
pubmed: 25910934
Hepatobiliary Pancreat Dis Int. 2019 Jun;18(3):255-265
pubmed: 31027910
Am J Physiol Renal Physiol. 2006 Jun;290(6):F1516-24
pubmed: 16403835
Trends Cell Biol. 2012 Jan;22(1):50-60
pubmed: 22001186
J Immunol. 2007 Feb 15;178(4):2458-68
pubmed: 17277153
Pharmacol Res. 2020 Apr;154:104170
pubmed: 30776422
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Am Soc Nephrol. 2016 Apr;27(4):1076-90
pubmed: 26286732
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1283-92
pubmed: 26267293
Cardiovasc Res. 2009 May 1;82(2):184-92
pubmed: 19017750
Cell Mol Immunol. 2006 Feb;3(1):11-9
pubmed: 16549044
Drugs. 2020 Jun;80(8):841-848
pubmed: 32385738
J Biol Chem. 2003 Nov 28;278(48):47408-15
pubmed: 13129923
Br J Pharmacol. 2016 Jun;173(11):1778-92
pubmed: 26990079
J Ovarian Res. 2016 Feb 12;9:4
pubmed: 26868273